Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald R Bowsher

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Bioanalysis|November 20, 2012
Application of commercial research-grade biomarker assays in drug development: is it time to create 'pharmaceutical-grade' kits?Ronald R Bowsher, William Nowatzke, Jeffrey M Sailstad, et al.
Diabetes Technology & Therapeutics|May 1, 2004
Relating glucose clamp profiles to reduction of blood glucose after insulin administrationJames R Woodworth, Daniel C Howey, Ronald R Bowsher, et al.
Bioanalysis|March 11, 2011
Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programsWilliam L Nowatzke, Kathryn Rogers, Edward Wells, et al.
Journal of Immunoassay & Immunochemistry|March 30, 2019
Development and validation of a noncompetitive electrochemiluminescence-based immunoassay (ECLIA) for specific determination of insulin lispro (Humalog®) in human serum to support pharmacokinetic assessmentsErica Simmons, Derrick Johnson, Richard Delhaye, et al.
The AAPS Journal|July 23, 2017
Recommendations for Systematic Statistical Computation of Immunogenicity Cut PointsViswanath Devanarayan, Wendell C Smith, Rocco L Brunelle, et al.
Aesthetic Surgery Journal|April 13, 2023
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar LinesShannon Humphrey, Jeffrey S Dover, Ronald R Bowsher, et al.
Toxins|January 20, 2023
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 TrialsConor J Gallagher, Ronald R Bowsher, Amanda Clancy, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 27, 2011
Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibodyJohn H Sloan, Bradley J Ackermann, Mark O'Dell, et al.
Scientific Reports|July 30, 2021
Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domainDerrick Johnson, Erica Simmons, Sanofar Abdeen, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 29, 2004
Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serumChad A Ray, Ronald R Bowsher, Wendell C Smith, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Bioanalysis|November 20, 2012
Application of commercial research-grade biomarker assays in drug development: is it time to create 'pharmaceutical-grade' kits?Ronald R Bowsher, William Nowatzke, Jeffrey M Sailstad, et al.
Diabetes Technology & Therapeutics|May 1, 2004
Relating glucose clamp profiles to reduction of blood glucose after insulin administrationJames R Woodworth, Daniel C Howey, Ronald R Bowsher, et al.
Bioanalysis|March 11, 2011
Unique challenges of providing bioanalytical support for biological therapeutic pharmacokinetic programsWilliam L Nowatzke, Kathryn Rogers, Edward Wells, et al.
Journal of Immunoassay & Immunochemistry|March 30, 2019
Development and validation of a noncompetitive electrochemiluminescence-based immunoassay (ECLIA) for specific determination of insulin lispro (Humalog®) in human serum to support pharmacokinetic assessmentsErica Simmons, Derrick Johnson, Richard Delhaye, et al.
The AAPS Journal|July 23, 2017
Recommendations for Systematic Statistical Computation of Immunogenicity Cut PointsViswanath Devanarayan, Wendell C Smith, Rocco L Brunelle, et al.
Aesthetic Surgery Journal|April 13, 2023
Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar LinesShannon Humphrey, Jeffrey S Dover, Ronald R Bowsher, et al.
Toxins|January 20, 2023
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 TrialsConor J Gallagher, Ronald R Bowsher, Amanda Clancy, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 27, 2011
Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibodyJohn H Sloan, Bradley J Ackermann, Mark O'Dell, et al.
Scientific Reports|July 30, 2021
Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domainDerrick Johnson, Erica Simmons, Sanofar Abdeen, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 29, 2004
Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serumChad A Ray, Ronald R Bowsher, Wendell C Smith, et al.
Pageof 4